Fundraising Fox
ThirtyFiveBio Limited
Oxford, GB · 4 known investors
Find your way into ThirtyFiveBio Limited
280 people in our graph can introduce you to the ThirtyFiveBio Limited team.
Sign up to see every warm intro you have to ThirtyFiveBio Limited
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ThirtyFiveBio Limited team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.
Founders & leadership
Investors · 4
How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements- Undisclosed amountbridge roundApr 2025
AbbVie Ventures, Canaan, Mayewell Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 2
Companies working in the same space as ThirtyFiveBio Limited.
Companies House · registry record
View on Companies House ↗- Registered name
- THIRTYFIVEBIO LIMITED
- Company number
- 13157735
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 26 Jan 2021
- Registered office
- 99 Park Drive, Milton, Abingdon, OX14 4RY
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 25 Jan 2026 · next due 8 Feb 2027
Current officers · 6
- Samantha Ann Harris — secretary, appointed 22 Jun 2022
- Brenton Karl Ahrens — director, appointed 13 Apr 2021
- Donmienne Doen Mun Leung — director, appointed 11 Mar 2025
- Nils Lonberg — director, appointed 28 May 2021
- Thomas David Mccarthy — director, appointed 26 Jan 2021
- James Westcott — director, appointed 29 Jun 2021
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does ThirtyFiveBio Limited do?
- ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.
- Who are ThirtyFiveBio Limited's investors?
- ThirtyFiveBio Limited's investors include Canaan Partners.
- Where is ThirtyFiveBio Limited headquartered?
- ThirtyFiveBio Limited is headquartered in Oxford, GB.